[en] Acute kidney injury (AKI) represents a worldwide public health issue of increasing incidence, with a significant morbi-mortality. AKI treatment mostly relies on supportive manoeuvres in the absence of specific target-oriented therapy. The pathophysiology of AKI commonly involves ischaemia/reperfusion (I/R) events, which cause both immune and metabolic consequences in renal tissue. Similarly, at the time of kidney transplantation (KT), I/R is an unavoidable event which contributes to early graft dysfunction and enhanced graft immunogenicity. Mesenchymal stromal cells (MSCs) represent a heterogeneous population of adult, fibroblast-like multi-potent cells characterized by their ability to differentiate into tissues of mesodermal lineages. Because MSC have demonstrated immunomodulatory, anti-inflammatory and tissue repair properties, MSC administration at the time of I/R and/or at later times has been hypothesized to attenuate AKI severity and to accelerate the regeneration process. Furthermore, MSC in KT could help prevent both I/R injury and acute rejection, thereby increasing graft function and survival. In this review, summarizing the encouraging observations in animal models and in pilot clinical trials, we outline the benefit of MSC therapy in AKI and KT, and envisage their putative role in renal ischaemic conditioning.
Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-1301
Li XC, Turka LA. An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol 2010; 6: 577-583
Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222
Mokarizadeh A, Delirezh N, Morshedi A et al. Microvesicles derived from mesenchymal stem cells: Potent organelles for induction of tolerogenic signaling. Immunol Lett. 2012; 147: 47-54
Bruno S, Grange C, Collino F et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One 2012; 7: E33115
Islam MN, Das SR, Emin MT et al. Mitochondrial transfer from bonemarrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012; 18: 759-765
Carrion F, Nova E, Luz P et al. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol Lett 2011; 135: 10-16
Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp Hematol 2009; 37: 1445-1453
Maggini J, Mirkin G, Bognanni I et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010; 5: E9252
Zhao ZG, Xu W, Sun L et al. Immunomodulatory function of regulatory dendritic cells induced by mesenchymal stem cells. Immunol Invest 2012; 41: 183-198
Souidi N, Stolk M, Seifert M. Ischemia-reperfusion injury: Beneficial effects of mesenchymal stromal cells. Curr Opin Organ Transplant 2013; 18: 34-43
Togel FE, Westenfelder C. Mesenchymal stem cells: A new therapeutic tool for AKI. Nat Rev Nephrol 2010; 6: 179-183
Seo-Mayer PW, Thulin G, Zhang L et al. Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. Am J Physiol Renal Physiol 2011; 301: F1346-F1357
Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 2002; 282: C227-C241
Bon D, Chatauret N, Giraud S et al. New strategies to optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol 2012; 8: 339-347
Ioannou A, Dalle Lucca J, Tsokos GC. Immunopathogenesis of ischemia/ reperfusion-Associated tissue damage. Clin Immunol 2011; 141: 3-14
Fuquay R, Renner B, Kulik L et al. Renal ischemia-reperfusion injury amplifies the humoral immune response. J Am Soc Nephrol 2013; 24: 1063-1072
Renner B, Strassheim D, Amura CR et al. B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol 2010; 185: 4393-4400
Jang HR, Gandolfo MT, Ko GJ et al. B cells limit repair after ischemic acute kidney injury. J Am Soc Nephrol 2010; 21: 654-665
Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med 2011; 17: 1391-1401
Bouma HR, Carey HV, Kroese FG. Hibernation: The immune system at rest? J Leukoc Biol 2010; 88: 619-624
Wever KE, Menting TP, Rovers M et al. Ischemic preconditioning in the animal kidney, a systematic review and meta-Analysis. PLoS One 2012; 7: E32296
Wever KE, Masereeuw R, Wagener FA et al. Humoral signalling compounds in remote ischaemic preconditioning of the kidney, a role for the opioid receptor. Nephrol Dial Transplant 2013; 28: 1721-1732
Togel F, Hu Z, Weiss K et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289: F31-F42
Liu H, Liu S, Li Y et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One 2012; 7: E34608
Eggenhofer E, Benseler V, Kroemer A et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3: 297
Cao H, Qian H, Xu Wet al. Mesenchymal stem cells derived from human umbilical cord ameliorate ischemia/reperfusion-induced acute renal failure in rats. Biotechnol Lett 2010; 32: 725-732
Chen YT, Sun CK, Lin YC et al. Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med 2011; 9: 51
Altun B, Yilmaz R, Aki T et al. Use of mesenchymal stem cells and darbepoetin improve ischemia-induced acute kidney injury outcomes. Am J Nephrol 2012; 35: 531-539
Xinaris C, Morigi M, Benedetti V et al. A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion. Cell Transplant 2013; 22: 423-436
Gatti S, Bruno S, DeregibusMC et al.Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 2011; 26: 1474-1483
Bruno S, Grange C, Deregibus MC et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009; 20: 1053-1067
Heemann U, Lutz J. Pathophysiology and treatment options of chronic renal allograft damage. Nephrol Dial Transplant 2013; 28: 2438-2446
Casiraghi F, Perico N, Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant 2013; 18: 51-58
Roemeling-van Rhijn M, Reinders ME, de Klein A et al. Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. Kidney Int 2012; 82: 748-758
Hara Y, Stolk M, Ringe J et al. In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. Transpl Int 2011; 24: 1112-1123
Seifert M, Stolk M, Polenz D et al. Detrimental effects of rat mesenchymal stromal cell pre-Treatment in a model of acute kidney rejection. Front Immunol 2012; 3: 202
Casiraghi F, Azzollini N, Todeschini M et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12: 2373-2383
Franquesa M, Herrero E, Torras J et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev 2012; 21: 3125-3135
Franquesa M, Hoogduijn MJ, Reinders ME et al. Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: Lessons learned from first clinical trials. Transplantation 2013; 96: 234-238
Perico N, Casiraghi F, Introna M et al. Autologous mesenchymal stromal cells and kidney transplantation: A pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6: 412-422
Perico N, Casiraghi F, Gotti E et al. Mesenchymal stromal cells and kidney transplantation: Pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int 2013; 26: 867-878